merged_cancer-screening-tests-cost.txt
<question_number>1</question_number>
<answer>Vastly improved colon cancer treatment</answer>
<question_number>2</question_number>
<answer>Studies repeatedly fail to show that screening extends life</answer>
<question_number>3</question_number>
<answer>The increase in screening did not accelerate the decline; the decline remained linear</answer>
<question_number>4</question_number>
<answer>That the mortality effect of screening is so small it can only be detected with very large clinical trials</answer>
<question_number>5</question_number>
<answer>A relative 33% reduction that amounts to only a one percentage point absolute decrease (from 3% to 2%)</answer>
<question_number>6</question_number>
<answer>Improved treatments can reduce mortality so significantly that the added benefit of screening is minimal</answer>
<question_number>7</question_number>
<answer>They may lower risk factors, contributing to reduced death rates independent of screening</answer>
<question_number>8</question_number>
<answer>The paradox is that despite heavy promotion and cost, screening shows only minimal reduction in death rates</answer>
<question_number>9</question_number>
<answer>Screening is widely endorsed to cut cancer deaths, yet its measurable impact is minimal while death rates decline chiefly due to other factors</answer>
<question_number>10</question_number>
<answer>Improved treatments, changing diets, and other risk‚Äêreducing exposures like certain medications</answer>